Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Regeneron Pharmaceuticals Inc (REGN34)

B3
Currency in BRL
78.70
+2.30(+3.01%)
Closed

REGN34 Income Statement

Advanced Income Statement
Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa6,557.68,497.116,071.712,172.913,117.2
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+27.44%+29.58%+89.14%-24.26%+7.76%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa3,215.13,766.95,297.65,152.96,254.8
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa3,342.54,730.210,774.17,0206,862.4
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+2.55%+41.52%+127.77%-34.84%-2.25%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa50.97%55.67%67.04%57.67%52.32%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa1,132.71,065.61,779.32,0262,629.2
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa+56.26%-5.92%+66.98%+13.87%+29.77%
aa.aaaa.aaaa.aaaa.aaaa.aa-----
aa.aaaa.aaaa.aaaa.aaaa.aa1,341.91,3461,824.92,115.92,631.3
aa.aaaa.aaaa.aaaa.aaaa.aa-209.2-280.4-45.6-89.9-2.1
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa2,209.83,664.68,994.84,9944,233.2
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-12.81%+65.83%+145.45%-44.48%-15.23%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa33.7%43.13%55.97%41.03%32.27%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa-30.218.5-11.5100.7422.9
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-7.09%+161.26%-162.16%+975.65%+319.96%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-30.2-56.9-57.3-59.4-73
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa-75.445.8160.1495.9
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa131.219.34.459-32.9
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa2,310.83,702.48,987.75,153.74,623.2
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa--88-48-255.1-186.1
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa2,429.13,810.49,325.84,858.84,199.3
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-4.87%+56.86%+144.75%-47.9%-13.57%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa37.04%44.84%58.03%39.91%32.01%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa313.3297.21,250.5520.4245.7
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa2,115.83,513.28,075.34,338.43,953.6
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa2,115.83,513.28,075.34,338.43,953.6
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-13.44%+66.05%+129.86%-46.28%-8.87%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa32.26%41.35%50.25%35.64%30.14%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa2,115.83,513.28,075.34,338.43,953.6
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa19.3832.6576.440.5137.05
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-14.47%+68.52%+133.99%-46.98%-8.53%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa18.4630.5271.9738.2234.77
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-13.29%+65.33%+135.81%-46.89%-9.03%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa109.2107.6105.7107.1106.7
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa114.6115.1112.2113.5113.7
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa2,420.13,900.59,2815,335.44,654.2
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-9.79%+61.17%+137.94%-42.51%-12.77%
EBITDA Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa36.91%45.9%57.75%43.83%35.48%
EBIT
aa.aa